Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026)

Catalyst Pharmaceuticals has reported FCF Margin for 9 years, with the latest figure at 39.87% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 259.0% year-over-year to 39.87%; the trailing twelve-month figure through Mar 2026 stood at 34.86% (down 1518.0% YoY), and the FY2025 full-year result was 35.42%, down 1324.0% from the prior year.
• FCF Margin for Q1 2026 stood at 39.87%, up from 29.39% in the prior quarter.
• The five-year high for FCF Margin was 72.15% in Q3 2022, with the low at 14.05% in Q1 2023.
• Historically, FCF Margin has averaged 42.3% across 5 years, with a median of 43.88% in 2023.
• Annual changes were most pronounced in 2024 — FCF Margin soared 2137 bps — and 2025, when it slumped 3456 bps.
• Catalyst Pharmaceuticals' FCF Margin stood at 65.96% in 2022, then fell by 24 bps to 50.25% in 2023, then decreased by 1 bps to 49.91% in 2024, then sank by 41 bps to 29.39% in 2025, then soared by 36 bps to 39.87% in 2026.
• The last three FCF Margin figures came in at 39.87% (Q1 2026), 29.39% (Q4 2025), and 21.86% (Q3 2025), per Business Quant data.